2023 Preclinical Form and Formulation for Drug Discovery Gordon Research Conference and Gordon Research Seminar

2023年药物发现临床前形式和制剂戈登研究会议和戈登研究研讨会

• 批准号: 10605746
• 负责人: Julie Champion
• 金额: $ 3.3万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-20 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10605746
• 关键词: Acceleration; Allergic Disease; Antiviral Agents; Artificial Intelligence; Biological; Biological Availability; Biological Products; Biological Response Modifier Therapy; Cell Therapy; Chemicals; Chemistry; Clinic; Clinical; Clinical Research; Communicable Diseases; Complex; Creativeness; Data; Developed Countries; Development; Disabled Persons; Discipline; Disease; Dose; Drug Formulations; Drug Industry; Engineering; Environment; Failure; Fees; Financial Support; Formulation; Fostering; Goals; Government; Health Priorities; Immune System Diseases; Industrialization; Knowledge; Laboratories; Leadership; Learning; Marketing; Medical; Medicine; Methodology; Methods; Microbe; Mission; Modality; Modeling; Molecular; Motivation; National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Disease; Nucleic Acids; Oncology; Participant; Patient Recruitments; Patients; Peptides; Performance; Pharmaceutical Preparations; Pharmacy (field); Postdoctoral Fellow; Proteins; Rare Diseases; Recruitment Activity; Research; Research Personnel; Role; Science; Scientist; Series; Solubility; Students; System; Techniques; Technology; Therapeutic; Training; Translating; Translational Research; Translations; Underrepresented Populations; United States National Institutes of Health; Vaccines; Woman; World Health Organization; career; cost; drug candidate; drug development; drug discovery; global health; graduate student; improved; in silico; innovation; insight; manufacture; meetings; microbial; microbiome; molecular scale; new technology; next generation; novel; novel therapeutics; pre-clinical; prevent; programs; recruit; small molecule; success; symposium; timeline; tool

Abstract Global health, rare diseases, and other unmet medical needs have unique challenges in formulation prediction, materials characterization, and delivery of chemical, biological, and cellular medicines. The purpose of the 2023 Gordon Research Conference and Seminar (GRC/GRS) on Preclinical Form and Formulation for Drug Discovery is to accelerate the translation of promising drug candidates into commercial medicines by: (1) disseminating the latest scientific and technical advances relevant to materials characterization, formulation and delivery of chemical, biological, and cellular medicines; (2) fostering a vibrant, inclusive, and diverse scientific network; (3) educating and engaging the next generation of scientists. This GRC/GRS brings together expertise and unpublished data on diverse therapeutics to highlight the form and formulation challenges and opportunities that span these modalities and integrate cross-cutting techniques and approaches. These therapeutics include bispecific and multi-functional small molecules, peptides, proteins, nucleic acids, and “living” microbial medicines with broad applications ranging from infectious diseases to oncology. Formulation and characterization technologies cover both novel experimental and in silico approaches, with the ultimate goal of discovering general principles and tools that can be applied to many drugs to prevent failure and inefficiency. Dissemination and discussion of new knowledge and technologies are necessary to enable broad use and further progress that will translate more drugs efficiently into the clinic. Form and formulation can also enable solutions to critical global health challenges, and this meeting will amplify the need for World Health Organization zone 4 stability and distribution requirements, low cost, and easy to administer formulation and delivery systems. This conference will share successes, continuing difficulties, and lessons learned from academic, industrial, government, and non-profit scientists to meet the needs of patients across the world. Beyond molecular and professional diversity, the program agenda and efforts to recruit participants reflect the commitment of the leadership team to an inclusive meeting with diverse participants including scientists from groups underrepresented in pharmaceutics, chemistry and engineering. An important component of this inclusivity is training the next generation of scientists and the combination of the Gordon Research Conference, for scientists at all career stages, and the Gordon Research Seminar, for graduate student and postdoctoral scientists, enables early career scientists from a broad range of backgrounds to share their research and interact personally with leaders in the field to grow their networks and nurture their career goals.

摘要 全球健康、罕见疾病和其他未得到满足的医疗需求在配方预测方面具有独特的挑战， 材料表征，以及化学、生物和细胞药物的输送。2023年的目的 戈登研究会议和研讨会(GRC/GRS)关于药物发现的临床前形式和配方 是通过以下方式加速将有前途的候选药物转化为商业药物：(1)宣传 与材料表征、配方和交付有关的最新科学和技术进展 化学、生物和细胞药物；(2)培育充满活力、包容和多样化的科学网络；(3) 教育和吸引下一代科学家。该GRC/GRS汇集了专业知识和 关于不同疗法的未发表数据，以突出形式和配方方面的挑战和机遇 跨越这些模式，整合贯穿各领域的技术和方法。这些疗法包括 双功能多功能小分子、多肽、蛋白质、核酸和“活”微生物药物 具有从传染病到肿瘤学的广泛应用。配方和表征 技术涵盖了新的实验方法和硅胶方法，最终目标是发现 可应用于许多药物以防止失效和低效的一般原则和工具。传播 以及对新知识和新技术的讨论是必要的，以便能够广泛使用和进一步取得进展 将更有效地将更多药物转化为临床药物。形式和公式还可以实现关键的全球解决方案 卫生挑战，本次会议将扩大世界卫生组织第四区稳定和 配送要求高、成本低、配方和输送系统易于管理。这次会议 将分享成功、持续的困难以及从学术界、产业界、政府和 非营利性科学家以满足世界各地患者的需求。除了分子和专业的多样性， 计划议程和招募参与者的努力反映了领导团队对 与不同参与者的包容性会议，包括来自制药学代表性不足群体的科学家， 化学和工程学。这种包容性的一个重要组成部分是培养下一代科学家 戈登研究会议，面向所有职业阶段的科学家，与戈登研究会议的结合 面向研究生和博士后科学家的研究研讨会，使早期职业科学家从广泛的 广泛的背景，分享他们的研究成果，并亲自与该领域的领导者互动，以发展他们的 并培养他们的职业目标。